Setup, so nobody has to ask: 97.1% · mazdutide.
I have worked this out and I would like someone to find the error, because I suspect there is one.
My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.
How many significant figures are actually justified here?
Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
The underlying point is that integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
Compare purity within a single laboratory on the same method, never across laboratories.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsConcretely, identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
More usefully, mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Stated carefully, the single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.
It helps to be literal here: the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Mechanically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
Compare purity within a single laboratory on the same method, never across laboratories.
edited 1 Jan 2025 by halvard_ness — added the placebo-arm figures
The relevant detail is that reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
If you are ranking vendors, specify a method and have all samples tested at the same place.
edited 17 Jan 2025 by Dr_Elias_Weiss — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.